THE IMPORANCE OF MITIGATING ANALYTE INTERACTIONS WITH METAL SURFACES IN HPLC SEPARATIONS OF SMALL MOLECULES

Significance of the Topic

The interaction of analytes with exposed metal surfaces in high-performance liquid chromatography (HPLC) systems can compromise data quality through peak tailing, signal loss and on-column reactions. Mitigating these interactions is critical for accurate quantification and reliable reproducibility, especially in pharmaceutical analysis where trace-level detection and compound stability are paramount.

Study Aims and Overview

This work compares a standard ultra-performance liquid chromatography (UPLC) system and column to versions featuring a novel hybrid surface technology (HST) implemented in the ACQUITY Premier platform. The study evaluates performance improvements for three small molecule drug analytes: hydrocortisone sodium phosphate, deferoxamine mesylate and clozapine.

Methodology

An experimental comparison involved parallel separations under identical gradient and mobile phase conditions, quantifying chromatographic performance across a range of mass loadings. Key steps included:

• Hydrocortisone sodium phosphate: UV detection over 2–200 ng, triplicate injections per level, ACQUITY UPLC BEH C18 columns, 10 mM ammonium formate (pH 3.0), acetonitrile gradient.
• Deferoxamine mesylate: Electrospray ionization mass spectrometry detection over 2–60 ng, triplicate injections for each load and ten consecutive 10 ng injections, ACQUITY UPLC HSS T3 columns, 10 mM ammonium formate (pH 3.0), acetonitrile gradient.
• Clozapine: UV detection for parent and N-oxide, series of injections at fixed load, ACQUITY UPLC BEH C18 columns, 10 mM ammonium hydroxide mobile phase, acetonitrile gradient.

Used Instrumentation

• Standard UPLC system with ACQUITY UPLC BEH C18 and HSS T3 columns.
• ACQUITY Premier UPLC system and columns featuring hybrid organic–inorganic surface coating on metal components.
• UV detectors for hydrocortisone and clozapine assays.
• Electrospray ionization mass spectrometer for deferoxamine quantitation.

Key Results and Discussion

• Hydrocortisone sodium phosphate: HST system yielded sharper, more symmetric peaks, steeper calibration slopes and substantially reduced relative standard deviations (RSD) at low loads (2, 20, 50 ng).
• Deferoxamine mesylate: Peak area RSD at 10 ng improved from 16.8 % (standard) to 2.1 % (HST) across ten injections, demonstrating enhanced reproducibility.
• Clozapine: Metal-catalyzed on-column oxidation to the N-oxide reached 2.05 % relative area after 13 injections on the standard column but was limited to 0.06 % on the HST column, indicating minimized artifact formation.

Benefits and Practical Applications

• Enhanced sensitivity and quantitative accuracy for metal-sensitive analytes.
• Reduced peak tailing and injection-to-injection variability.
• Suppression of unwanted on-column reactions, improving assay specificity.
• Direct applicability to pharmaceutical quality control, bioanalysis and metabolic profiling.

Future Trends and Possibilities

Continued development of surface chemistries may extend HST benefits to a broader range of analyte classes and chromatographic platforms. Integration with microscale and preparative systems, as well as tailored coatings for specific compound families, represents promising directions for enhancing analytical robustness.

Conclusion

The introduction of hybrid surface technology in UPLC systems effectively mitigates analyte–metal interactions that degrade chromatographic performance. By delivering higher signal intensity, lower variability and suppressed artifact formation, HST-coated instruments and columns provide a reliable solution for the analysis of small molecule pharmaceuticals.

References

1. Wakamatsu A, Morimoto K, Shimizu M, Kudoh S. J Sep Sci. 2005;28:1823–1830.
2. Myers DP et al. J Chromatogr A. 2013;1319:57–64.
3. DeLano M et al. Anal Chem. 2021;93(14):5773–5781.
4. Smith KM, Wilson ID, Rainville PD. Anal Chem. 2020;93(2):1009–1015.
5. Gilar M, DeLano M, Gritti J. Chromatogr A. 2021;1650:462247.
6. Nguyen JM et al. Bioanalysis. 2021;13(6):1233–1244.
7. Birdsall RE et al. J Chromatogr B. 2021;1179:122700.
8. Plumb RS et al. J Pharm Biomed Anal. 2021;200:114076.
9. Tanna N et al. J Chromatogr B. 2021;1179:122825.